Why the study?
Right ventricular outflow dysfunction is nearly universal after repaired tetralogy of Fallot, increasing late morbidity and mortality as the adolescent and adult survivor population grows.
Design
American Heart Association scientific statement
Authors
Loading...
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“There are still many areas in the long-term management of RVOT dysfunction in repaired TOF that remain unclear and could use data-driven decision making. One unanswered question will be whether the availability of midterm data on the recent self-expanding transcatheter pulmonary valve prostheses (designed expressly for patients with larger patched RVOTs) result in broadening of indications for PVR? Given the recent experience with transcatheter aortic valve replacement (TAVR) being increasingly utilized in younger and healthier patients, this seems likely.”
May inform RVOT management in repaired TOF; hypothesis-generating and should not yet change practice.
This AHA scientific statement provides updated comprehensive guidance on the long-term management, surveillance, and intervention timing for right ventricular outflow tract dysfunction in patients with repaired tetralogy of Fallot.
Geva et al. (2024) conducted a review in Right ventricular outflow tract dysfunction in repaired tetralogy of Fallot. Management and therapeutic strategies was evaluated. The American Heart Association scientific statement reviews contemporary management, surveillance, and therapeutic strategies for right ventricular outflow tract dysfunction in repaired tetralogy of Fallot.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: